Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 245

1.

Evolution of rifampicin treatment for tuberculosis.

Grobbelaar M, Louw GE, Sampson SL, van Helden PD, Donald PR, Warren RM.

Infect Genet Evol. 2019 Oct;74:103937. doi: 10.1016/j.meegid.2019.103937. Epub 2019 Jun 24.

PMID:
31247337
2.

Droplets, dust and guinea pigs: an historical review of tuberculosis transmission research, 1878-1940.

Donald PR, Diacon AH, Lange C, Demers AM, von Groote-Bidlingmaier F, Nardell E.

Int J Tuberc Lung Dis. 2018 Sep 1;22(9):972-982. doi: 10.5588/ijtld.18.0173. Review. Erratum in: Int J Tuberc Lung Dis. 2018 Oct 1;22(10):1244.

PMID:
30092861
3.

Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis.

Jaganath D, Schaaf HS, Donald PR.

J Antimicrob Chemother. 2017 Jul 1;72(7):1848-1857. doi: 10.1093/jac/dkx051. Review.

4.

Time Trends in Sputum Mycobacterial Load and Two-Day Bactericidal Activity of Isoniazid-Containing Antituberculosis Therapies.

De Jager V, van der Merwe L, Venter A, Donald PR, Diacon AH.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02088-16. doi: 10.1128/AAC.02088-16. Print 2017 Apr.

5.

Use of corticosteroids in tuberculous meningitis.

Donald PR, Van Toorn R.

Lancet. 2016 Jun 25;387(10038):2585-2587. doi: 10.1016/S0140-6736(16)30770-X. No abstract available.

PMID:
27353808
6.

Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.

Bekker A, Schaaf HS, Draper HR, van der Laan L, Murray S, Wiesner L, Donald PR, McIlleron HM, Hesseling AC.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2171-9. doi: 10.1128/AAC.02600-15. Print 2016 Apr.

7.

Chemotherapy for Tuberculous Meningitis.

Donald PR.

N Engl J Med. 2016 Jan 14;374(2):179-81. doi: 10.1056/NEJMe1511990. No abstract available.

PMID:
26760090
8.

A review of the use of ethionamide and prothionamide in childhood tuberculosis.

Thee S, Garcia-Prats AJ, Donald PR, Hesseling AC, Schaaf HS.

Tuberculosis (Edinb). 2016 Mar;97:126-36. doi: 10.1016/j.tube.2015.09.007. Epub 2015 Oct 19. Review.

PMID:
26586647
9.

Successful Treatment of a Child With Extensively Drug-Resistant Tuberculous Meningitis.

Alsleben N, Garcia-Prats AJ, Hesseling AC, Willemse M, Donald PR, Schaaf HS.

J Pediatric Infect Dis Soc. 2015 Sep;4(3):e41-4. doi: 10.1093/jpids/piu120. Epub 2014 Dec 23.

PMID:
26407442
10.

Simultaneous staining of sputum smears for acid-fast and lipid-containing Myobacterium tuberculosis can enhance the clinical evaluation of antituberculosis treatments.

Kayigire XA, Friedrich SO, van der Merwe L, Donald PR, Diacon AH.

Tuberculosis (Edinb). 2015 Dec;95(6):770-779. doi: 10.1016/j.tube.2015.08.001. Epub 2015 Aug 13.

PMID:
26318558
11.

Para-aminosalicylic acid: the return of an old friend.

Donald PR, Diacon AH.

Lancet Infect Dis. 2015 Sep;15(9):1091-1099. doi: 10.1016/S1473-3099(15)00263-7. Epub 2015 Aug 12. Review.

PMID:
26277036
12.

Antituberculosis drugs in children.

Schaaf HS, Garcia-Prats AJ, Donald PR.

Clin Pharmacol Ther. 2015 Sep;98(3):252-65. doi: 10.1002/cpt.164. Epub 2015 Jul 14. Review.

PMID:
26095192
13.

The diagnostic value of cerebrospinal fluid chemistry results in childhood tuberculous meningitis.

Solomons RS, Visser DH, Donald PR, Marais BJ, Schoeman JF, van Furth AM.

Childs Nerv Syst. 2015 Aug;31(8):1335-40. doi: 10.1007/s00381-015-2745-z. Epub 2015 May 15.

PMID:
25976864
14.

N-acetyltransferase genotypes and the pharmacokinetics and tolerability of para-aminosalicylic acid in patients with drug-resistant pulmonary tuberculosis.

Sy SK, de Kock L, Diacon AH, Werely CJ, Xia H, Rosenkranz B, van der Merwe L, Donald PR.

Antimicrob Agents Chemother. 2015 Jul;59(7):4129-38. doi: 10.1128/AAC.04049-14. Epub 2015 May 11.

15.

Fluoroquinolones for the treatment of tuberculosis in children.

Thee S, Garcia-Prats AJ, Donald PR, Hesseling AC, Schaaf HS.

Tuberculosis (Edinb). 2015 May;95(3):229-45. doi: 10.1016/j.tube.2015.02.037. Epub 2015 Feb 14. Review.

PMID:
25797610
16.

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.

Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM.

Lancet. 2015 May 2;385(9979):1738-1747. doi: 10.1016/S0140-6736(14)62002-X. Epub 2015 Mar 18.

PMID:
25795076
17.

Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline.

Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Hutchings J, Burger DA, Schall R, Mendel CM.

Am J Respir Crit Care Med. 2015 Apr 15;191(8):943-53. doi: 10.1164/rccm.201410-1801OC.

PMID:
25622149
18.

Pre-treatment mycobacterial sputum load influences individual on-treatment measurements.

Diacon AH, van der Merwe L, Demers AM, Von Groote-Bidlingmaier F, Venter A, Donald PR.

Tuberculosis (Edinb). 2014 Dec;94(6):690-4.

PMID:
25444765
19.

In reply: Acquired drug-resistance because of pharmacokinetic variability in a young child with tuberculosis.

Garcia-Prats AJ, Donald PR, Schaaf HS.

Pediatr Infect Dis J. 2014 Nov;33(11):1205-6. doi: 10.1097/INF.0000000000000404. No abstract available.

PMID:
25361415
20.

Acquired drug resistance during inadequate therapy in a young child with tuberculosis.

Garcia-Prats AJ, Willemse M, Seifart HI, Jordaan AM, Werely CJ, Donald PR, Schaaf HS.

Pediatr Infect Dis J. 2014 Aug;33(8):883-5. doi: 10.1097/INF.0000000000000336.

PMID:
25222312
21.

The North American contribution to our knowledge of childhood tuberculosis and its epidemiology.

Donald PR.

Int J Tuberc Lung Dis. 2014 Aug;18(8):890-8. doi: 10.5588/ijtld.13.0915. Review.

PMID:
25199001
22.

Uniform research case definition criteria differentiate tuberculous and bacterial meningitis in children.

Solomons RS, Wessels M, Visser DH, Donald PR, Marais BJ, Schoeman JF, van Furth AM.

Clin Infect Dis. 2014 Dec 1;59(11):1574-8. doi: 10.1093/cid/ciu665. Epub 2014 Aug 19.

PMID:
25139968
23.

Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.

de Kock L, Sy SK, Rosenkranz B, Diacon AH, Prescott K, Hernandez KR, Yu M, Derendorf H, Donald PR.

Antimicrob Agents Chemother. 2014 Oct;58(10):6242-50. doi: 10.1128/AAC.03073-14. Epub 2014 Aug 11.

24.

Death and disability: the outcomes of tuberculous meningitis.

Graham SM, Donald PR.

Lancet Infect Dis. 2014 Oct;14(10):902-4. doi: 10.1016/S1473-3099(14)70872-2. Epub 2014 Aug 6. No abstract available.

PMID:
25108336
25.

Dose regimen of para-aminosalicylic acid gastro-resistant formulation (PAS-GR) in multidrug-resistant tuberculosis.

Kibleur Y, Brochart H, Schaaf HS, Diacon AH, Donald PR.

Clin Drug Investig. 2014 Apr;34(4):269-76. doi: 10.1007/s40261-014-0172-7.

PMID:
24488376
26.

Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.

Zvada SP, Denti P, Donald PR, Schaaf HS, Thee S, Seddon JA, Seifart HI, Smith PJ, McIlleron HM, Simonsson US.

J Antimicrob Chemother. 2014 May;69(5):1339-49. doi: 10.1093/jac/dkt524. Epub 2014 Jan 31.

27.

Time to positivity in liquid culture predicts colony forming unit counts of Mycobacterium tuberculosis in sputum specimens.

Diacon AH, van der Merwe L, Demers AM, von Groote-Bidlingmaier F, Venter A, Donald PR.

Tuberculosis (Edinb). 2014 Mar;94(2):148-51. doi: 10.1016/j.tube.2013.12.002. Epub 2013 Dec 18.

PMID:
24456754
28.

The early bactericidal activity of antituberculosis drugs.

Diacon AH, Donald PR.

Expert Rev Anti Infect Ther. 2014 Feb;12(2):223-37. doi: 10.1586/14787210.2014.870884. Epub 2014 Jan 6. Review.

PMID:
24392698
29.

Short intensified treatment in children with drug-susceptible tuberculous meningitis.

van Toorn R, Schaaf HS, Laubscher JA, van Elsland SL, Donald PR, Schoeman JF.

Pediatr Infect Dis J. 2014 Mar;33(3):248-52. doi: 10.1097/INF.0000000000000065.

PMID:
24168978
30.

Requirements for the clinical evaluation of new anti-tuberculosis agents in children.

Donald PR, Ahmed A, Burman WJ, Cotton MF, Graham SM, Mendel C, McIlleron H, Mac Kenzie WR, Nachman S, Schaaf HS, Starke JR, Wingfield C, Hesseling AC.

Int J Tuberc Lung Dis. 2013 Jun;17(6):794-9. doi: 10.5588/ijtld.12.0567.

PMID:
23676164
31.

Tuberculous meningitis.

Schoeman JF, Donald PR.

Handb Clin Neurol. 2013;112:1135-8. doi: 10.1016/B978-0-444-52910-7.00033-7. Review.

PMID:
23622321
32.

Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis.

Diacon AH, Dawson R, Von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, Conradie A, Erondu N, Ginsberg AM, Egizi E, Winter H, Becker P, Mendel CM.

Antimicrob Agents Chemother. 2013 May;57(5):2199-203. doi: 10.1128/AAC.02243-12. Epub 2013 Mar 4.

33.

Early bactericidal activity of new drug regimens for tuberculosis - Authors' reply.

Diacon AH, Donald PR, Mendel CM.

Lancet. 2013 Jan 12;381(9861):112-3. doi: 10.1016/S0140-6736(13)60042-2. No abstract available.

PMID:
23312747
34.

Edith Lincoln, an American pioneer of childhood tuberculosis.

Donald PR.

Pediatr Infect Dis J. 2013 Mar;32(3):241-5. doi: 10.1097/INF.0b013e31827d3d12.

PMID:
23190783
35.

Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation.

Liwa AC, Schaaf HS, Rosenkranz B, Seifart HI, Diacon AH, Donald PR.

J Trop Pediatr. 2013 Apr;59(2):90-4. doi: 10.1093/tropej/fms053. Epub 2012 Nov 21.

PMID:
23174991
36.

From magic mountain to table mountain.

Diacon AH, von Groote-Bidlingmaier F, Donald PR.

Swiss Med Wkly. 2012 Aug 22;142:w13665. doi: 10.4414/smw.2012.13665. eCollection 2012. Review.

37.

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.

Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK.

Lancet. 2012 Sep 15;380(9846):986-93. doi: 10.1016/S0140-6736(12)61080-0. Epub 2012 Jul 23.

PMID:
22828481
38.

Nutritional status and its response to treatment of children, with and without HIV infection, hospitalized for the management of tuberculosis.

Schaaf HS, Cilliers K, Willemse M, Labadarios D, Kidd M, Donald PR.

Paediatr Int Child Health. 2012 May;32(2):74-81. doi: 10.1179/2046905512Y.0000000008.

PMID:
22595213
39.

Phase II dose-ranging trial of the early bactericidal activity of PA-824.

Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, van Niekerk C, Erondu N, Ginsberg AM, Becker P, Spigelman MK.

Antimicrob Agents Chemother. 2012 Jun;56(6):3027-31. doi: 10.1128/AAC.06125-11. Epub 2012 Mar 19.

40.

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, McNeeley DF.

Antimicrob Agents Chemother. 2012 Jun;56(6):3271-6. doi: 10.1128/AAC.06126-11. Epub 2012 Mar 5.

41.

A proposed comprehensive classification of tuberculosis disease severity in children.

Wiseman CA, Gie RP, Starke JR, Schaaf HS, Donald PR, Cotton MF, Hesseling AC.

Pediatr Infect Dis J. 2012 Apr;31(4):347-52. doi: 10.1097/INF.0b013e318243e27b. Review.

PMID:
22315002
42.

Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa.

Dramowski A, Morsheimer MM, Jordaan AM, Victor TC, Donald PR, Schaaf HS.

Int J Tuberc Lung Dis. 2012 Jan;16(1):76-81. doi: 10.5588/ijtld.11.0360.

43.

Multidrug-resistant tuberculosis of the spine in children--characteristics from a high burden setting.

Seddon JA, Donald PR, Vlok GJ, Schaaf HS.

J Trop Pediatr. 2012 Oct;58(5):341-7. doi: 10.1093/tropej/fmr104. Epub 2011 Dec 14.

PMID:
22170512
44.

Paediatric use of second-line anti-tuberculosis agents: a review.

Seddon JA, Hesseling AC, Marais BJ, McIlleron H, Peloquin CA, Donald PR, Schaaf HS.

Tuberculosis (Edinb). 2012 Jan;92(1):9-17. doi: 10.1016/j.tube.2011.11.001. Epub 2011 Nov 25. Review.

PMID:
22118883
45.

Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome.

Seddon JA, Hesseling AC, Willemse M, Donald PR, Schaaf HS.

Clin Infect Dis. 2012 Jan 15;54(2):157-66. doi: 10.1093/cid/cir772. Epub 2011 Nov 3.

46.

Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.

Thee S, Seddon JA, Donald PR, Seifart HI, Werely CJ, Hesseling AC, Rosenkranz B, Roll S, Magdorf K, Schaaf HS.

Antimicrob Agents Chemother. 2011 Dec;55(12):5560-7. doi: 10.1128/AAC.05429-11. Epub 2011 Oct 3.

47.

Time to liquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents.

Diacon AH, Maritz JS, Venter A, van Helden PD, Dawson R, Donald PR.

Clin Microbiol Infect. 2012 Jul;18(7):711-7. doi: 10.1111/j.1469-0691.2011.03626.x. Epub 2011 Aug 18.

48.

Pyrazinamide pharmacokinetics and efficacy in adults and children.

Donald PR, Maritz JS, Diacon AH.

Tuberculosis (Edinb). 2012 Jan;92(1):1-8. doi: 10.1016/j.tube.2011.05.006. Epub 2011 Jul 26. Review.

PMID:
21795116
49.

Pharmacokinetics of ethionamide in children.

Thee S, Seifart HI, Rosenkranz B, Hesseling AC, Magdorf K, Donald PR, Schaaf HS.

Antimicrob Agents Chemother. 2011 Oct;55(10):4594-600. doi: 10.1128/AAC.00379-11. Epub 2011 Jul 25.

50.

Antituberculosis drug-induced hepatotoxicity in children.

Donald PR.

Pediatr Rep. 2011 Jun 16;3(2):e16. doi: 10.4081/pr.2011.e16.

Supplemental Content

Loading ...
Support Center